Literature DB >> 1354957

Heterogeneous responses of recombinant human thyrotropin receptor to immunoglobulins from patients with Graves' disease.

T Endo1, M Ohmori, M Ikeda, E Anzai, T Onaya.   

Abstract

Non-thyroid mammalian cells, CHO-K1 cells, stably expressing human thyrotropin receptor (CHO-TSH-R cells) were used for the assay of thyroid stimulating antibody (TSAb) activities of IgGs from 24 patients with Graves' disease and we compared them with the values obtained in porcine thyroid cells. A significant positive correlation was observed between the results given by CHO-TSH-R cells (hTSAb) and porcine thyrocytes (pTSAb) (r = 0.94, p less than 0.001). However, we found that hTSAb values of IgGs from 5 patients were extremely different from their hTSAb values. Four out of these 5 IgGs showed strong pTSAb activity but exhibited a weak or negative hTSAb activity. Conversely, one out of 5 autoantibodies was very strong for hTSAb but its pTSAb was low. These heterogeneous responses of recombinant hTSH-R to Graves' IgGs suggest that there exist different types of TSAb and also that the epitope(s) for TSAb may be different from case to case.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1354957     DOI: 10.1016/s0006-291x(05)81560-8

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  How one TSH receptor antibody induces thyrocyte proliferation while another induces apoptosis.

Authors:  Syed A Morshed; Risheng Ma; Rauf Latif; Terry F Davies
Journal:  J Autoimmun       Date:  2013-08-17       Impact factor: 7.094

Review 2.  Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies.

Authors:  Terry F Davies; Rauf Latif
Journal:  Expert Opin Ther Targets       Date:  2015-03-13       Impact factor: 6.902

3.  Clinical significance of classification of Graves' disease according to the characteristics of TSH receptor antibodies.

Authors:  W B Kim; H K Chung; Y J Park; D J Park; H K Lee; B Y Cho
Journal:  Korean J Intern Med       Date:  2001-09       Impact factor: 2.884

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.